Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129130 | 0.95 | ALDH1A1 (0.39) | ALDH1A1NPSR1CTDSP1 | |
| SCHEMBL616066 | 0.93 | ALDH1A1 (0.42) | ALDH1A1NPSR1CTDSP1 | |
| SCHEMBL131208 | 0.90 | — | — | |
| SCHEMBL24814669 | 0.83 | — | — | |
| SCHEMBL23067675 | 0.82 | — | — | |
| SCHEMBL758309 | 0.81 | CTDSP1 (0.32) | CTDSP1 | |
| SCHEMBL17848458 | 0.79 | — | — | |
| SCHEMBL11971122 | 0.79 | — | — | |
| SCHEMBL3608665 | 0.76 | — | — | |
| SCHEMBL442000 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| EP-3186239-B1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9873680-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3186239-A1 | ANTIRETROVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016033243-A9 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-24 | — | — | US | disclosed |
| WO-2016033243-A1 | ANTIRETROVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| WO-2003004494-A1 | PYRIDAZINONE COMPOUND AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160083368-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | ALDH1A1 372/4885NPSR1 3511/4885CTDSP1 1389/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | ALDH1A1 580/4885NPSR1 859/4885CTDSP1 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.